Gadeta appoints Marco Londei as Chief Executive Officer

Strengthens management team as Gadeta receives approval to start first clinical study in multiple myeloma

07 April 2020, Utrecht, Netherlands: Gadeta, focused on the discovery and development of novel cancer immunotherapies based on gamma delta T cell receptors (TCRs), announces the appointment of Marco Londei as Chief Executive Officer (CEO) to lead the Company as it transitions from a preclinical stage company to a clinical stage company. The company also announces it has received FDA approval to commence its first clinical study in multiple myeloma.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH